Based in New York City, LEXEO Therapeutics is an integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science addressing application of the transformational science of gene therapy to some of the worlds most devastating genetic and acquired diseases. The firm's pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicines Department of Genetic Medicine. Beyond LEXEO Therapeutics lead programs focused on both rare and non-rare monogenic (single gene mutation) diseases companys preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicines Department of Genetic Medicine to help advance the companys pre-clinical pipeline.
